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ABSTRACT
Background: Mucinous carcinoma (MC) is found in 10%–15% of colorectal cancer 
(CRC) patients. It differs from the common adenocarcinoma (AC) in histopathological 
appearance and clinical behavior.
Methods: Genome-wide DNA copy number and survival data from MC and AC 
primary CRC samples from patients from two phase III trials (CAIRO and CAIRO2) 
was compared. Chromosomal copy number data from The Cancer Genome Atlas 
(TCGA) was used for validation. Altogether, 470 ACs were compared to 57 MCs.
Results: MC showed a reduced amount of copy number aberrations (CNAs) 
compared with AC for the CAIRO/CAIRO2 cohort, with a median amount of CNAs 
that was 1.5-fold lower (P = 0.002). Data from TCGA also showed a reduced amount 
of CNAs for MC. MC samples in both cohorts displayed less gain at chromosome 
20q and less loss of chromosome 18p. A high rate of chromosomal instability was a 
strong negative prognostic marker for survival in MC patients from the CAIRO cohorts 
(hazard ratio 15.60, 95% CI 3.24–75.05).
Conclusions: Results from this study indicate that the distinct MC phenotype is 
accompanied by a different genetic basis when compared with AC and show a strong 
association between the rate of chromosomal instability and survival in MC patients.
INTRODUCTION
Colorectal cancer (CRC) is categorized 
by histological subtype according to the WHO 
classification. The majority of patients (~85%) is 
diagnosed with an adenocarcinoma not otherwise 
specified (AC). Mucinous adenocarcinoma (MC) is 
detected in 10%-15% of patients and is characterized by 
abundant extracellular mucin lakes that comprise more 
than half of the tumor volume. [1] MC differs from AC 
in both clinical and pathological presentation. [2, 3] MC 
is more frequently found in the proximal colon and at 
a higher stage at presentation than AC. [2, 3] Also, the 
response to therapies varies between MC and AC as 
patients with MC show a poorer response to palliative 
chemotherapy compared with AC, resulting in a worse 
survival. [4–7] These findings suggest a distinct genetic 
background of MC.
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There are two major pathways through which 
genomic instability can occur in CRC, namely 
chromosomal instability (CIN) and microsatellite 
instability (MSI). CIN is found in the majority (~85%) 
of CRCs and is a type of genetic instability in which 
chromosomal aberrations accumulate, leading to an 
altered expression of tumor suppressor genes and 
oncogenes. [8] MSI accounts for the remaining 15% of 
CRCs and is caused by a defective DNA mismatch repair 
mechanism that leads to a clonal change in the number of 
microsatellites. [9] Tumors with MSI are more commonly 
found in MC patients compared with AC patients, and 
exhibit less (CNAs). [5, 10]
Although MSI is more common in MC than in AC, 
the vast majority of MCs supposedly still develops through 
the CIN pathway. Unfortunately, most large-scale 
genomic studies of CRC did not address differences 
between histological subtypes and focused mainly on AC. 
Specific DNA CNAs that cause gene dosage effects in 
oncogenes and tumor suppressor genes, typically occur 
during adenoma to carcinoma progression, and thus 
are an integral part of the pathogenesis of CRC. [11] 
Therefore, analysis of DNA CNAs between MC and AC 
in a sufficiently large collection of samples may generate 
more insight into an early and possibly diverging event in 
cancer development.
In this study we use DNA copy number data from 
primary tumor samples of patients with MC or AC 
who participated in two phase III clinical trials. These 
data were used to test whether the distinct MC and AC 
phenotypes relate to differences in genomic profiles. 
Molecular characterization of MC may improve our 
understanding of the reduced response rate to systemic 
therapies and therefore contributes to the development of 
targeted treatment modalities for MC.
MATERIALS AND METHODS
Patients and materials
For this study we used clinical and genome data 
of patients from two randomized controlled trials and 
validated our findings with data from TCGA.
CAIRO and CAIRO2 cohorts
We used high resolution array comparative genomic 
hybridization (aCGH) data that were generated from DNA 
isolated from formalin-fixed and paraffin-embedded (FFPE) 
primary tumors, which was hybridized against paired 
germ-line DNA samples. The processes of sample selection, 
DNA isolation and aCGH data have been described 
previously. [12] Samples were derived from patients 
who participated in the CAIRO study (CKTO 2002–07, 
ClinTrials.gov; NCT00312000) [13] or CAIRO2 study 
(CKTO 2005–02, ClinTrials.gov; NCT00208546) [14] 
of the Dutch Colorectal Cancer Group (DCCG). These 
phase III trials had different systemic regimens as first-line 
treatment for CRC patients with metastatic disease. In the 
CAIRO study, patients were randomly assigned to either 
sequential or combination treatment with capecitabine 
and irinotecan, followed by oxaliplatin. In the CAIRO2 
study patients were randomized between treatment with 
capecitabine, oxaliplatin and bevacizumab, with or without 
the addition of cetuximab. All patients had given written 
informed consent prior to study entry, which also included 
translational research on tumor tissue. aCGH was performed 
on a subset of the patients from these trials. [12] In the 
CAIRO2 study the aCGH was only performed on material 
from the control arm since the addition of cetuximab in the 
experimental arm yielded a worse outcome. Furthermore, 
only tumors with paired germ-line tissue, and with areas 
of high tumor cell percentage available (>70%) had been 
included. A total of 349 high quality DNA copy number 
profiles were generated. Tumors were classified according 
to the guidelines of the World Health Organization. If 
more than 50% of the tumor consisted of extracellular 
mucin it was classified as MC. [1] AC was defined as a 
tumor without extracellular mucin. Only tumors that were 
categorized as MC or AC were included in our analyses. 
Tumors with microsatellite instability (MSI) usually exhibit 
limited CNAs, and therefore form a separate entity among 
CRCs. These patients (N = 31) were excluded from the 
present study. In the current study DNA copy number 
profiles of 17 MC and 135 AC patients from the CAIRO 
study and 12 MC and 100 AC patients from the CAIRO2 
study were compared.
The cancer genome atlas cohort
To validate findings from the CAIRO cohorts, copy 
number information for MC and AC samples from The 
Cancer Genome Atlas (TCGA) data portal was analyzed. On 
27 January 2014 all available colon adenocarcinoma level 3 
copy number data were downloaded from the TCGA Data 
Portal using the Data Matrix (https://tcga-data.nci.nih.gov/
tcga/dataAccessMatrix.htm). TCGA copy number data had 
been generated with Affymetrix SNP 6.0 arrays (Santa Clara, 
USA). Only data obtained from primary tumors was used. 
The histopathological designation as provided by TCGA 
was used, and only tumors that were categorized as MC or 
AC were selected. Furthermore, MSI tumors were excluded 
from the analyses. In total, DNA copy number profiles of 28 
MC and 235 AC patients were compared.
Clinicopathological data
For each patient, the following clinicopathological 
characteristics were available: age, gender, site of primary 
tumor, number of metastatic sites involved, invasion 
depth, lymph node status, MSI status and histological 
subtype. Tumors from the TCGA cohort were classified as 
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proximal if they were found in the cecum, ascending colon 
or transverse colon, up to the splenic flexure, and were 
classified as distal if they were found in the descending 
colon or sigmoid colon. MSI status was determined by 
immunohistochemistry with antibodies against MLH1, 
MSH2, MSH6 and PMS2. MSI analysis was performed 
on indication by PCR followed by GeneScan analysis for 
MSI markers (BAT25, BAT26, BAT40, D2S123, D5S346, 
D17S250). [15, 16] Differences in baseline characteristics 
between groups were determined using Fisher’s 
exact testing. Statistical analyses were two-sided and 
p-values < 0.05 were considered significant.
Processing of aCGH and SNP array data
Array CGH was performed using customized 
Agilent oligonucleotide arrays. Methods of DNA 
extraction, labeling, hybridization and scanning were 
previously described [17] and the exact array design can 
be found online in the Gene Expression Omnibus (GEO) 
(GPL8687 http://www.ncbi.nlm.nih.gov/geo). The probes 
were mapped to human reference sequence GRCh37/hg19 
(February 2009). The statistical programming language R 
was used for data processing. The quality of the aCGH 
DNA copy number profiles was assessed by calculating the 
median absolute deviation (MAD) from the log2ratios of 
signal intensities from tumor- and paired germ-line DNA. 
A MAD value of 0.4 and smaller was used as a quality 
criterion, which all DNA copy number profiles passed. 
A wave-smoothing algorithm was applied on the profiles 
and the profiles were median normalized and corrected for 
tumor cell percentage using the R package ‘CGHcall’. [18] 
For segmentation the R package ‘DNAcopy’ was used. [19] 
Next, mode normalization was performed. Subsequently, 
the DNA copy number (deletion, loss, neutral, gain, or 
amplification) was determined for each segment using the 
R package ‘CGHcall’. [12] This data was used to generate 
genome-wide frequency plots and box plots with the 
number of aberrations. For further analyses the dimensions 
of the aCGH data set were reduced using the R package 
‘CGHregions’ (averror = 0.01). [20] This step reduced the 
calls into subregions. Each subregion consisted of a series 
of neighboring clones on the chromosome whose aCGH-
signature was shared by all clones. With this step 2010 
subregions were obtained with a median size of 0.5 Mb 
(interdecile range = 110 kb–2 Mb).
The TCGA level 3 SNP6 data consisted of copy 
number values (log2ratios) generated with ‘nocnv’ 
segmentation. For the genome-wide frequency plots, 
information was extracted from the downloaded files 
with LINUX shell and BEDTools. [21] By extracting the 
genomic positions of all segment ends, a file with unique 
genomic positions was made. This gave 52654 genomic 
positions distributed over all chromosomes. Next, for 
each TCGA sample the log2 ratio at these positions was 
collected. In R these copy number values were converted 
into calls. The threshold was set as previously described. 
[22] Values lower than -0.23 were assigned copy number 
loss, and values higher than 0.2 were assigned gain, 
all other values were assigned neutral. These values 
correspond to 30% of the tumor cells with that CNA. 
This data was used to generate the frequency plots using 
functions of the R package ‘CGHbase’.
Analysis of the level of chromosomal instability
For each sample we counted the number of probes 
called as loss, neutral or gain and subsequently calculated 
the percentage of probes with an aberrant call. The 
distribution of this level of chromosomal instability was 
plotted in box-plots. To assess whether the distribution of 
MC and AC samples was different, the Wilcoxon rank sum 
test was used (also known as Mann-Whitney test).
Identification of regions with differential copy 
number
DNA copy number information of the 2010 
subregions was analyzed in a supervised way. MCs from 
both CAIRO studies were compared with ACs from 
the same studies. Per sample group, the frequencies 
of losses, neutrals and gains were determined for each 
region. To calculate the statistical significance of DNA 
copy number differences between MC and AC the 
Wilcoxon rank sum test was used, and a correction for 
multiple testing was performed with the Benjamini-
Hochberg procedure. An adjusted p-value < 0.01 was 
considered statistically significant. The TCGA data 
were used for validation of the differential subregions 
identified with the CAIRO/CAIRO2 samples. Frequency 
plots were generated for subregions that showed 
differences in copy number and a Wilcoxon rank sum 
test was performed on the calls to determine significant 
DNA copy number differences between MC and AC, 
followed by correction for multiple testing with the 
Benjamini-Hochberg procedure.
Survival analysis
To determine the impact of CIN on survival in MC 
and AC patients, groups were divided into CIN high and 
CIN low. The threshold was set at the median level of CIN 
of all samples of the CAIRO cohorts which was 29.66%. 
Patients who demonstrated a CIN rate below the median 
were considered CIN low and consequently, patients who 
demonstrated a CIN rate that was above the median, were 
considered CIN high. Overall survival (OS) was defined 
as the interval between the date of randomization until the 
date of death of any cause or until last follow-up. Patients 
who were alive at the end of follow-up were censored 
in the survival analyses. OS curves were estimated 
using the Kaplan–Meier method and compared with the 
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log-rank test. Multivariable analysis of OS was performed 
using the Cox proportional hazard model. Statistical 
analyses were performed with the statistical software 
package SPSS 20.0 (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Clinicopathological data of the CAIRO, 
CAIRO2 and TCGA cohort
The baseline characteristics on MC and AC 
patients from the CAIRO/CAIRO2 cohort are presented 
in Supplementary Table S1. MC patients were more 
commonly over 60 years of age than AC patients (86.3% 
versus 62.5%, P = 0.04). There were no other significant 
differences in clinicopathological characteristics between 
MC and AC patients. Data on survival between AC and 
MC in advanced stage disease were published previously 
on these series. [5] Clinicopathological data on colon 
cancer patients from the TCGA cohort is presented in 
Supplementary Table S2. In MC patients from the TCGA 
cohort, tumors were more commonly located in the 
proximal colon than in AC patients (78.6% versus 49.4%, 
P = 0.004). The distribution of tumors was not different 
in the CAIRO/CAIRO2 cohort. There were no further 
substantial differences in baseline characteristics.
Different copy number profiles between  
MC and AC
The frequency of CNAs in MC and AC patients 
from the CAIRO/CAIRO2 and TCGA cohorts are 
depicted in Figure 1. These genome-wide profiles of 
CNAs of MC and AC patients appeared rather similar 
in both cohorts, but overall MCs displayed a lower 
level of chromosomal instability (Figure 2, left). In 
the MCs from the CAIRO/CAIRO2 cohort a median 
of 21% of the genome showed either deletions, losses, 
gains or amplifications, compared with 31% for the 
ACs, P = 0.002. For the TCGA cohort this was 19% 
for MC versus 29% for AC, respectively (P = 0.0002). 
In the CAIRO/CAIRO2 cohort there were particularly 
differences in the overall frequencies of the gains between 
AC and MC (Supplementary figure S1).
Next, analyses were performed to further identify 
chromosomal subregions with significant differential 
copy number. We identified 234 significantly differential 
subregions in the CAIRO/CAIRO2 cohort (P = 0.01; 
Figure 3). These subregions were located on chromosomes 
5, 6, 7, 8, 10, 11, 13, 16, 17, 18 and 20.
Validation in TCGA data
To confirm the findings from the CAIRO/CAIRO2 
cohort, data from TCGA were analyzed. The TCGA data 
not only represents another patient cohort, but also a 
different methods to determine DNA CNAs, since single 
channel SNP arrays were used, rather than CGH arrays. In 
addition, no paired normal DNA was used and DNA was 
isolated from fresh frozen material. MC samples displayed 
a reduced rate of CNAs than AC samples (Figure 2, 
right). Furthermore, MC samples in this cohort showed 
a significantly differential copy number for chromosome 
18 and 20 (Figure 4), but not for the other chromosomes 
with significant differential subregions for the CAIRO/
CAIRO2 cohort (chromosomes 5, 6, 7, 8, 10, 11, 13, 16 
and 17). This included 13q gain, which showed a highly 
significant difference between AC and MC in the CAIRO/
CAIRO2 cohort, while in the TCGA cohort this could not 
be confirmed (Supplementary Figure S2).
Different copy numbers at chromosome  
18 and 20
MC patients displayed significantly less losses 
at chromosome 18 compared with AC patients in both 
cohorts. In the TCGA cohort, this comprised nearly 
the entire chromosome, but for the CAIRO/CAIRO2 
cohort, this was mainly restricted to regions of the p-arm 
(Figure 4). The significant loci on 18p for the CAIRO/
CAIRO2 cohort were merged into one region of main 
interest of 14 Mb, which involved almost the entire p-arm 
(18p11.32–18p11.21). For this region of interest, 34% of 
MC patients showed a loss in the CAIRO/CAIRO2 cohort, 
compared with 69% of AC patients.
In the TCGA data these percentages were 14% and 
64% respectively. At the q-arm of chromosome 20 both the 
CAIRO/CAIRO2 and TCGA cohorts showed less gains 
in MC patients compared with AC patients (Figure 4). 
This region of interest at chromosome 20 was 33 Mb 
and comprised essentially the entire q-arm (20q11.21–
20q13.33). A gain at this region was found in 52% MC 
patients in the CAIRO/CAIRO2 cohort, while AC patients 
showed 93% gain or amplification. The percentages of these 
gains were 46% and 84%, respectively for the TCGA data.
Survival is related to CIN status in MC patients
The relation between survival and either a high or 
low rate of CIN was explored. There were 112 AC and 
20 MC patients in the CIN low group versus 123 AC 
and 9 MC patients in the CIN high group. OS rates in 
MC patients were dependent on the rate of chromosomal 
instability. MC CIN high patient had a statistically 
significant poorer OS compared with MC CIN low patients. 
MC CIN high patients had a median OS of 6.6 months 
(95% CI 4.8–8.4) versus 19.4 months (95% CI 11.7–27.0) 
for MC CIN low patients (Figure 5a). An OS difference 
according to CIN status was not observed in AC patients, 
with a median OS of 19.7 months (95% CI 17.8–21.7) 
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for AC CIN high patients compared with 21.2 months 
(95% CI 16.3–26.1) in AC CIN low patients (Figure 5b). 
Interestingly, MC CIN low patients had an OS that 
was comparable to that of AC patients. Also, in the 
multivariable Cox regression analysis a high rate of CIN 
was a strong negative prognostic marker for OS in MC 
patients from the CAIRO cohorts with a hazard ratio of 
15.60 (95% CI 3.24–75.05, Supplementary Table S3).
DISCUSSION
MC is considered a unique subtype of CRC based on 
its histopathological appearance and clinical behavior. This 
study investigated whether the distinct visual microscopic 
pathological characteristics of MC are associated with 
different genetic aberrations when compared with AC in 
MSS primary tumors.
Figure 1: Comparison of the overall frequencies of DNA CNAs between MC and AC. Genome-wide frequency plots of DNA 
CNAs detected in the CAIRO/CAIRO2 A. and TCGA B. cohorts. The x-axis displays clones on the array ordered by chromosomal map 
positions of the clones. The y-axis displays the percentage of tumors with gains (above zero; blue) or losses (below zero; red). Boundaries 
of chromosomes are indicated by dotted lines.
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In CRC, CIN and MSI are two well-defined genomic 
pathways that are involved in carcinogenesis. MSI is found 
in approximately 15% of CRCs, but is more commonly 
found in MCs than in ACs. [5, 9, 10, 23] Although MSI 
and CIN are not mutually exclusive, CNAs are far less 
common in MSI than MSS tumors. [24, 25] In the present 
series of MSS CRCs an overall lower level of genetic 
instability was observed in MC compared with AC. As to 
specific DNA CNAs, the frequency of gain of chromosome 
20q and the frequency of loss of chromosome 18p was 
significantly lower in MC. Chromosomal gains of 20q 
and losses of 18p are among the most common molecular 
aberrations in CIN induced CRCs and since their 
occurrence is associated with progression from adenoma 
to carcinoma they are considered early genetic events. 
[11, 26] It should therefore be noted that these regions are 
consequently most prone to reach statistical significance 
if there are overall differences in genetic instability as 
we observed for AC versus MC. Notwithstanding, these 
regions could be less contributory in MC development.
Amplification of 20q is an early molecular event 
and considered one of the key events that may induce the 
malignant process. [11, 27, 28] Gain of a chromosomal 
region at 20q is present in over 60% of CRCs. [25, 28, 29] 
There are several common regions of overlap of the 
highest level of gains at the 20q arm, which makes 
it plausible that multiple genes are involved in CRC 
development. The exact mechanism through which this 
occurs has not yet been elucidated, but an increasing 
number of genes that would be responsible for this 
20q amplicon-driven progression has been identified. 
[27, 30,  31] Gain of 20q has also been associated with a 
poor prognosis in CRC patients. [32] Previously, we found 
that prognosis of MC patients in advanced stage disease 
was worse compared with AC patients, due to a decreased 
response to palliative chemotherapy. [5] Our group 
identified chromosomal regions that were associated with 
a decreased responsiveness to the addition of irinotecan in 
advanced colorectal cancer. [12] However, these specific 
regions did not differ between MC and AC patients in the 
current study. The poor response to chemotherapy may 
be related to the deviant pattern along which metastatic 
disease spreads in MC patients. Compared with AC, MC 
is less likely to present with liver metastases only, whereas 
intra-abdominal metastases are observed in more than half 
of all cases with advanced disease. [33] One study that 
analyzed CNAs between patients with different metastatic 
patterns showed that gain of the 20q chromosomal arm 
was associated with liver-specific metastases, suggesting a 
role in the process of liver metastasis in CRC. [34] Patients 
who did not develop metastatic disease and patients with 
peritoneal metastases showed a gain of 20q less frequently. 
[34, 35] These findings fit very well with the aberrant 
metastatic pattern that has been observed in MC patients.
Losses of chromosome 18q and 18p are seen in 
two third of CRC patients. [36] Especially loss of 18q 
is a well-known aberration that has been associated with 
adenoma to carcinoma progression. However, loss of 
18p has also been found to be an early genetic change in 
primary CRC. [26, 37] It is unknown what genes on 18p 
Figure 2: Levels of CIN. For each sample the percentage of probes with an aberrant call was calculated. The box plots show per cohort 
the distribution of the percentage of probes with an aberrant call for the AC and MC samples. In both cohorts a lower median chromosomal 
instability for MC is observed.
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can be held accountable for the malignant progression. 
Gain of chromosome 13q is found in approximately half 
of CRCs. [29, 36, 38] and is associated with adenoma to 
carcinoma progression as well. [37] Interestingly, in the 
present study we found less gain for virtually the entire 
13q-arm in the CAIRO/CAIRO2 cohort, but this could not 
be confirmed with data from the TCGA cohort.
We found that a high level of CIN was associated 
with a poor outcome in MC patients, but not in AC 
patients. Previously, CIN has been associated with a 
poor prognosis, mostly in stage II and III CRC. [39] 
Apparently, this also accounts for MC stage IV patients. 
It has been suggested that abnormalities of the spindle 
checkpoint drive CIN. [40] Overexpression of AURKA 
(located on Chr 20q13, encoding the kinase Aurora-A) 
or loss of CHEK2 (located on Chr 22q12, encoding 
the DNA damage checkpoint kinase Chk2) increase 
microtubule assembly, promoting CIN. [41] The mitotic 
checkpoint may thus provide a novel therapeutic target 
to improve overall survival and/or to modify response to 
chemotherapy. [42]
It is increasingly acknowledged that CRC is a 
heterogeneous disease and there is ample evidence that 
tumors differ on a molecular level. Previously, two studies 
that used allelotyping PCR for a few loci showed that 
lower allelic imbalance is associated with MC. [43, 44] 
In the current study, based on data from two independent 
cohorts we conclude that the distinct phenotype of MC is 
accompanied by a different genome-wide genetic profile 
when compared with AC, marked by a reduced rate of 
DNA CNAs overall, as well as less frequent gain of 20q 
and less frequent loss of 18p. Therefore, it may be possible 
that CIN plays a less prominent role in MC development. 
The differences in CNAs were found in a metastatic cohort 
(CAIRO/CAIRO2 cohort) as well as in a cohort with 
more early stage tumors (TCGA cohort), supporting the 
view that there is a genetic distinction between MC and 
AC that transcends the stage of presentation. Evidently, 
the consequences of chromosomal aberrations on gene 
expression levels eventually determine the functional 
phenotype. This study did not provide an insight into 
the specific pathway along which MCs developed, but 
was able to demonstrate that MC differed from AC on 
a molecular level. Since the DNA copy number effect 
was seen for large chromosomal regions and throughout 
the genome, the effects are probably due to genomic 
imbalance and alterations at multiple genes rather than 
specific genes. Further studies that can assess molecular 
Figure 3: Distribution of differentiated regions. Genome plot depicting a linear view of the chromosomes and distribution of the 
regions with a significant differential DNA copy number frequency between MC and AC patients in the CAIRO/CAIRO2 cohort. The 234 
regions are localized on 11 chromosomes.
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differences between MC and AC with a higher resolution 
(e.g. next-generation sequencing) are therefore needed. 
Previously, it has been reported that mutation rates in 
the therapeutically important RAS/RAF/MAPK and 
PI3K/AKT pathways are significantly higher in MC than 
in AC. [5, 45–47] Moreover, MC is more frequently 
associated with MSI and the CpG island methylator 
(CIMP) phenotype. [45, 46, 48] Although these features 
Figure 4: Frequency plots of DNA CNAs in chromosome 18 and chromosome 20. Detailed view of chromosomes with the 
differential regions of the CAIRO/CAIRO2 cohort that are validated in the TCGA data set. The y-axis displays the percentage of tumors 
with gain (above zero; blue) or los (below zero; red). The chromosomes represent ideograms with chromosomal bands. The corrected 
p-values obtained with statistical significance testing and correction for multiple testing are depicted in boxes below the plots. Black 
represents adjusted P < 0.01 and indicated a significant difference in DNA copy number between AC and MC; grey represents adjusted 
P > 0.01 and no indication of a significant difference. The significant loci obtained from the CAIRO/CAIRO2 cohort on 18p and 20q can be 
merged into two regions of main interest: chr18:122131–13971462 and chr20:29833609–62880524. For the region of interest on p18 34% 
of MC patients showed a loss in the CAIRO/CAIRO2 cohort, compared with a loss in 69% in AC patients. For the region of interest on q20 
52% of MC patients in the CAIRO/CAIRO2 cohort showed a gain, while AC patients showed 93% gain or amplification.
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are not exclusive for MC patients, they do suggest that 
MC may develop through an alternative genetic instability 
pathway than CIN, which may explain the distinct tumor 
behavior and response to therapies. Due to low number it 
was not possible to compare differences in copy number 
changes between MSI MC and MSS MC patients in 
this study. It will be important to further investigate the 
molecular background of MC to increase knowledge on 
tumor behavior and to explore opportunities for targeting 
therapies. These data will enable clinicians to improve 
prediction of the course of disease and response to 
systemic treatment.
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